STAT3 and TP53 mutations associate with poor prognosis in
anaplastic large cell lymphoma

J 2021

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

LOBELLO, Cosimo, Boris TICHÝ, Vojtěch BYSTRÝ, Lenka RADOVÁ, Daniel FILIP et. al.

Basic information

Original name

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

Authors

LOBELLO, Cosimo (380 Italy, belonging to the institution), Boris TICHÝ (203 Czech Republic, belonging to the institution), Vojtěch BYSTRÝ (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Daniel FILIP (703 Slovakia, belonging to the institution), Marek MRÁZ (203 Czech Republic, belonging to the institution), I.A. MONTES-MOJARRO, N. PROKOPH, H. LAROSE, H.C. LIANG, G.G. SHARMA, L. MOLOGNI, D. BELADA, K. KAMARADOVA, F. FEND, C. GAMBACORTI-PASSERINI, O. MERKEL, Suzanne Dawn TURNER (826 United Kingdom of Great Britain and Northern Ireland, belonging to the institution), Andrea JANÍKOVÁ (203 Czech Republic, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Leukemia, London, Nature Publishing Group, 2021, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 12.883

RIV identification code

RIV/00216224:14740/21:00119058

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1038/s41375-020-01093-1

UT WoS

000593816000001

Keywords in English

ALCL

Abstract

V originále

Systemic anaplastic large cell lymphoma (sALCL) encompasses two distinct clinical entities of T-cell non-Hodgkin lymphoma: anaplastic lymphoma kinase-positive (ALK+) ALCL and ALK-negative (ALK−) ALCL. These entities are characterized by either the presence or absence of an ALK translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK−, with a 5-year overall survival (OS) of 70–80% versus 40–60%, respectively, [1,2,3]. Furthermore, more than 30% of ALK+ ALCL patients relapse [4, 5]. Despite the distinction between the two sALCL subtypes, frontline treatment for adults is similar and is based on CHOP or CHOEP, instead pediatric ALCL patients are mainly treated following the ALCL99 protocol [6,7,8]. Whilst high-throughput genomic studies in sALCL have shown recurrent genetic alterations, their association with outcome has not been fully investigated [9,10,11,12,13]. In this study, the mutational landscape of sALCL patient tumors was investigated to discover potential biomarkers that may improve risk stratification and patient management.

Links

GA19-15737S, research and development project

Name: Alternativní mechanismy deregulace p53 dráhy u chronické lymfocytární leukémie

Investor: Czech Science Foundation, Alternative mechanisms of deregulation of the p53 pathway in chronic lymphocytic leukemia

GJ19-23424Y, research and development project

Name: Imunogenika v sekvencování následující generace: Dešifrování patogenetických mechanismů u lymfoproliferativních poruch

Investor: Czech Science Foundation

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

675712, interní kód MU

Name: ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer (Acronym: ALKATRAS)

Investor: European Union, MSCA Marie Skłodowska-Curie Actions (Excellent Science)

90132, large research infrastructures

Name: NCMG II

Citovat

LOBELLO, Cosimo, Boris TICHÝ, Vojtěch BYSTRÝ, Lenka RADOVÁ, Daniel FILIP, Marek MRÁZ, I.A. MONTES-MOJARRO, N. PROKOPH, H. LAROSE, H.C. LIANG, G.G. SHARMA, L. MOLOGNI, D. BELADA, K. KAMARADOVA, F. FEND, C. GAMBACORTI-PASSERINI, O. MERKEL, Suzanne Dawn TURNER, Andrea JANÍKOVÁ and Šárka POSPÍŠILOVÁ. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia. London: Nature Publishing Group, 2021, vol. 35, No 5, p. 1500-1505. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-020-01093-1.

@article{1781892,
   author = {Lobello, Cosimo and Tichý, Boris and Bystrý, Vojtěch and Radová, Lenka and Filip, Daniel and Mráz, Marek and MontesandMojarro, I.A. and Prokoph, N. and Larose, H. and Liang, H.C. and Sharma, G.G. and Mologni, L. and Belada, D. and Kamaradova, K. and Fend, F. and GambacortiandPasserini, C. and Merkel, O. and Turner, Suzanne Dawn and Janíková, Andrea and Pospíšilová, Šárka},
   article_location = {London},
   article_number = {5},
   doi = {http://dx.doi.org/10.1038/s41375-020-01093-1},
   keywords = {ALCL},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma},
   url = {https://www.nature.com/articles/s41375-020-01093-1},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1781892
AU  - Lobello, Cosimo - Tichý, Boris - Bystrý, Vojtěch - Radová, Lenka - Filip, Daniel - Mráz, Marek - Montes-Mojarro, I.A. - Prokoph, N. - Larose, H. - Liang, H.C. - Sharma, G.G. - Mologni, L. - Belada, D. - Kamaradova, K. - Fend, F. - Gambacorti-Passerini, C. - Merkel, O. - Turner, Suzanne Dawn - Janíková, Andrea - Pospíšilová, Šárka
PY  - 2021
TI  - STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
JF  - Leukemia
VL  - 35
IS  - 5
SP  - 1500-1505
EP  - 1500-1505
PB  - Nature Publishing Group
SN  - 08876924
KW  - ALCL
UR  - https://www.nature.com/articles/s41375-020-01093-1
N2  - Systemic anaplastic large cell lymphoma (sALCL) encompasses two distinct clinical entities of T-cell non-Hodgkin lymphoma: anaplastic lymphoma kinase-positive (ALK+) ALCL and ALK-negative (ALK−) ALCL. These entities are characterized by either the presence or absence of an ALK translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK−, with a 5-year overall survival (OS) of 70–80% versus 40–60%, respectively, [1,2,3]. Furthermore, more than 30% of ALK+ ALCL patients relapse [4, 5]. Despite the distinction between the two sALCL subtypes, frontline treatment for adults is similar and is based on CHOP or CHOEP, instead pediatric ALCL patients are mainly treated following the ALCL99 protocol [6,7,8]. Whilst high-throughput genomic studies in sALCL have shown recurrent genetic alterations, their association with outcome has not been fully investigated [9,10,11,12,13]. In this study, the mutational landscape of sALCL patient tumors was investigated to discover potential biomarkers that may improve risk stratification and patient management.
ER  -

LOBELLO, Cosimo, Boris TICHÝ, Vojtěch BYSTRÝ, Lenka RADOVÁ, Daniel FILIP, Marek MRÁZ, I.A. MONTES-MOJARRO, N. PROKOPH, H. LAROSE, H.C. LIANG, G.G. SHARMA, L. MOLOGNI, D. BELADA, K. KAMARADOVA, F. FEND, C. GAMBACORTI-PASSERINI, O. MERKEL, Suzanne Dawn TURNER, Andrea JANÍKOVÁ and Šárka POSPÍŠILOVÁ. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. \textit{Leukemia}. London: Nature Publishing Group, 2021, vol.~35, No~5, p.~1500-1505. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-020-01093-1.

Detailed Information on Publication Record